CD8A and neoplasm: Gal3 impairs IFN-Ƴ secretion by CD4+ and CD8+ T lymphocytes; indeed, GCS-100 combined with therapeutic vaccination promotes cytotoxicity and cytokine secretion, resulting in increased tumor rejection [88].